Dr. Jonathan Galli Completes James T. Lubin Fellowship Training
The James T. Lubin Clinician Scientist Fellowship Award, established in 2008, supports the post-residency training of clinicians committed to careers in academic medicine specializing in rare neuroimmune disorders of the CNS (e.g., TM, AFM, MOGAD, ADEM, NMOSD, and ON) clinical care and research.
This program supports up to two years of clinical care and research training in an environment where clinicians learn to use the most current scientific tools to treat and advance knowledge about rare neuroimmune disorders. After completing the program, Fellows are prepared for a combined clinical and research career, directing robust research programs important to TM, AFM, ADEM, MOGAD, NMOSD, and ON in their clinical department.
Dr. Jonathan Galli recently completed his James T. Lubin Fellowship. Dr. Galli received his medical degree from the University of Vermont College of Medicine in Burlington, VT, and completed his neurology residency at The University of Utah in Salt Lake City, UT, where he worked with Fellowship mentor, Dr. Stacey Clardy. During his fellowship, Dr. Galli received ongoing training in the diagnosis, treatment, and long-term management of patients with rare neuroimmune disorders. He also had significant exposure to other rare autoimmune neurological conditions, including encephalitis and stiff-person syndrome. He has since started an independent clinic where he is managing patients with these conditions. As part of his fellowship training, he conducted research to look for biomarkers in individuals with NMOSD. The research investigated whether individuals have aquaporin¬4 (AQP¬4) autoantibodies prior to their symptom onset of NMOSD, and also looked for other inflammatory biomarkers.
Dr. Galli noted: “From a research standpoint, we continue to work towards the end of our NMO in the Department of Defense project, with sample submission just accepted. We should finish/publish this within the next year or so. I am also working with our new fellow to finish a project characterizing TM in the VA system, which should be published within the year. I am also submitting for a clinical trial using a drug in NMO.
I was also fortunate enough to host the recent SRNA regional symposium from the University of Utah in Salt Lake City, UT. Despite COVID19 forcing the symposium to move to a virtual platform, we were able to expand the event to a more inclusive, international event!”